Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Sensei Biotherapeutics, Inc. and changed its name to Faeth Therapeutics, Inc. in June 2026. The company was incorporated in 1999 and is headquartered in Rockville, Maryland.
Frequently asked questions
What sector does Faeth Therapeutics, Inc. (FTH) operate in?
Faeth Therapeutics, Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Faeth Therapeutics, Inc. (FTH) current stock price?
As of the latest data, Faeth Therapeutics, Inc. stock price is $19.10, with a previous close of $16.83. Faeth Therapeutics, Inc. gained $2.27 in the last trading session, representing a 13.46% increase.
What is Faeth Therapeutics, Inc. (FTH) current market capitalization?
Faeth Therapeutics, Inc. market cap is approximately 493.42 million.
What is Faeth Therapeutics, Inc. (FTH) Earnings Per Share (EPS)?
The trailing EPS is -$60.86, and the forward EPS is -$4.49.
What is Faeth Therapeutics, Inc. (FTH) EBITDA?
Faeth Therapeutics, Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -15.98 million.
Does Faeth Therapeutics, Inc. (FTH) pay dividends?
No. Faeth Therapeutics, Inc. does not pay a dividend.
What is Faeth Therapeutics, Inc. (FTH) beta (volatility) score?
Faeth Therapeutics, Inc. has a beta of -0.280, indicating lower volatility than the overall market.
